ICBMT 2025

[OP01] Oral Presentation 1
Date & Time	September 11 (Thu), 09:00-10:00
Chair(s)	Yeon Jung Lim (Chungnam National University College of Medicine, Korea) Dae Sik Kim (Korea University College of Medicine, Korea)
Speaker(s)	09:00-09:10	Comparative Analysis of Pretransplant Reduced Toxicity Conditioning Regimens Using TBI vs. Non-TBI in Adult Patients with Acute Lymphoblastic Leukemia Kyung Won Park (College of Medicine, The Catholic University of Korea, Korea)
	09:10-09:20	A Real-World Data Analysis Comparing Total Body Irradiation versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Jae Won Yoo (College of Medicine, The Catholic University of Korea, Korea)
	09:20-09:30	Comparative Analysis between Imatinib-Based versus Ponatinib-Based Frontline Therapy in Adult Patients with Ph-Positive Acute Lymphoblastic Leukemia Kyoung Il Min (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	Single-Center Experience of 87 Pediatric T-ALL Patients Receiving Allogeneic HSCT: Superior Survival in CR1 with Protective cGVHD Senlin Zhang (Children's Hospital of Soochow University, China)
	09:40-09:50	Treatment of Post-Transplantation Relapse in Patients with Acute Lymphoblastic Leukemia in the Era of Various Targeted Agents: Transplantation or Not Jaehyun Ahn (College of Medicine, The Catholic University of Korea, Korea)
	09:50-10:00	Clinical Outcomes of CD19/CD22 CAR-T versus Blinatumomab as Bridging Therapy to Allo-HSCT in Pediatric r/r B-ALL Zihan Chen (Children's Hospital of Soochow University, China)

[OP02] Oral Presentation 2
Date & Time	September 11 (Thu), 09:00-10:00
Chair(s)	Jae-Sook Ahn (Chonnam National University Medical School, Korea) Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
Speaker(s)	09:00-09:10	RNA Sequencing Based Fusion Detection in Acute Myeloid Leukemia: From Clinical Validation to Interpretation Strategies Namsoo Kim (Aerospace Medical Center, Korea)
	09:10-09:20	Validation of Harmonized Criteria for Transplant-Associated Thrombotic Microangiopathy: A Reassessment of Diagnosis and Prognosis in AML Patients Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea)
	09:20-09:30	Real-World Outcomes of Allogeneic Transplantation in AML Patients Aged 70 and Older by Remission Status Ka Young Kim (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	Prognostic Significance of Multi-Parametric MRD and Clinical Integration in CBF-AML Undergoing Autologous Hematopoietic Stem Cell Transplantation Hohyung Nam (College of Medicine, The Catholic University of Korea, Korea)
	09:40-09:50	A Nationwide Multicenter Registry Analysis of Allogeneic Transplantation in Older Adults with AML in Korea Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea)
	09:50-10:00	Molecular-Measurable Residual Disease (MRD) During Induction and Consolidation Has Better Prognostic Value than Flow-MRD in Predicting Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia Dingding Dong (Beijing Children’s Hospital, Capital Medical University, China)

[OP03] Oral Presentation 3
Date & Time	September 11 (Thu), 09:00-10:00
Chair(s)	Sun-Young Kong (National Cancer Center, Korea) Byung-Su Kim (College of Medicine, The Catholic University of Korea, Korea)
Speaker(s)	09:00-09:10	Focusing on FLT4 to Exploit Anti-Leukemic Precision Medicine through Integrative Immunomodulatory Tools within the Marrow Microenvironment Su Jung Park (College of Medicine, The Catholic University of Korea, Korea)
	09:10-09:20	Transcriptomic Insights into Mesenchymal Stem Cell-Derived Exosome-Mediated Ex Vivo Expansion of Hematopoietic Stem Cells Kunye Kwak (Korea University College of Medicine, Korea)
	09:20-09:30	Stable and Relatively Effective Engraftment of Bone Marrow Stromal Cells in a Murine Model of Syngeneic and Allogeneic Bone Marrow Transplantation Aleksei Bigildeev (National Medical Research Center for Hematology, Russia)
	09:30-09:40	Targeted Gene Sequencing Identifies a High-Risk Subgroup and Associated Gene Signature in Diffuse Large B-Cell Lymphoma Ho Cheol Jang (Chonnam National University Medical School, Korea)
	09:40-09:50	Predictive Molecular Biomarkers for Hypomethylating Agent Response in AML Patients through Integrative Omics Analysis Taek Gyu Lee (Yonsei University College of Medicine, Korea)
	09:50-10:00	Establishment of a Novel Culture Protocol for the Large-Scale Generation of Functional Third-Party-Derived Multivirus-Specific T Cells Takahiro Tomoda (Institute of Science Tokyo (SCIENCE TOKYO), Japan)

[OP04] Oral Presentation 4
Date & Time	September 11 (Thu), 09:00-10:00
Chair(s)	Hyoung Soo Choi (Seoul National University College of Medicine, Korea) Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea)
Speaker(s)	09:00-09:10	Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years Deepesh Lad (Leukemia/Bone Marrow Transplant Program of British Columbia, Canada)
	09:10-09:20	Adverse Events to Cryopreserved Hematopoietic Stem Cell Infusion: Experience from a Single Institution Chieh-Wen Kuo (National Taiwan University Children's Hospital, Taiwan)
	09:20-09:30	Reduced Dose Post Transplant Cyclophosphamide Regimes as Standard Graft Versus Host Disease Prophylaxis in Haploidentical Stem Cell Transplant in Acute Leukaemia; Real World Experience in National Transplant Centre in Malaysia Tien Gen Wong (Hospital Ampang, Malaysia)
	09:30-09:40	Successful Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Low Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin Hee Young Ju (Sungkyunkwan University School of Medicine, Korea)
	09:40-09:50	Ex Vivo ab+ T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan Conditioning in Pediatric Primary HLH: A Comparative Analysis with Matched Donors Sung Han Kang (University of Ulsan College of Medicine, Korea)
	09:50-10:00	Modified EASIX Score on Day 7 Predicts Survival and Non-Relapse Mortality in Pediatric Acute Leukemia Undergoing Haploidentical Stem Cell Transplantation Kai Cui (Children's Hospital of Soochow University, China)

[PL01] Plenary Session 1 September 11 (Thu), 10:30-11:50		Room A
Chair(s)	Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea)

10:30-11:10

Local Maintenance of GVHD by Progenitor-like T Cells

Warren D. Shlomchik

University of Pittsburgh School of Medicine, USA

Abstract CV
11:10-11:50

Optimization of Hematopoietic Stem Cell Transplantation using Drugs and Cellular Therapies

Hyoung Jin Kang

Seoul National University College of Medicine, Korea

Abstract CV

[LS01] Luncheon Symposium 1 (Sanofi Aventis Korea) September 11 (Thu), 12:00-12:40		Room A
Chair(s)	Won-Sik Lee (Inje University College of Medicine, Korea)

12:00-12:40

Belumosudil for Severe cGVHD: Insights from a Real-World Observational Study

Jiong Hu

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

Abstract CV

[LS02] Luncheon Symposium 2 (Johnson & Johnson Innovative Medicine) September 11 (Thu), 12:00-12:40		Room B
Chair(s)	Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)

12:00-12:40

Optimizing Treatment with Teclistamab in Triple Class-Exposed Multiple Myeloma: Highlighting the MajesTEC-1 Asian Results and Clinical Experience

Tadao Ishida

Japanese Red Cross Medical Center, Japan

Abstract CV

[LS03] Luncheon Symposium 3 (AbbVie Korea) September 11 (Thu), 12:00-12:40		Room C
Chair(s)	Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)

12:00-12:40

Venetoclax + HMA in 1L Unfit AML: Bridging Clinical Trials and Real-world Practice

Ofir Wolach

Davidoff Cancer Center, Rabin Medical Center, Israel

Abstract CV

[LS04] Luncheon Symposium 4 (Pfizer Korea) September 11 (Thu), 12:00-12:40		Room D
Chair(s)	Jin Seok Kim (Yonsei University College of Medicine, Korea)

12:00-12:40

A New Horizon of Multiple Myeloma Treatments Focusing on Elrexfio® Clinical Data

Shinsuke Iida

Nagoya City University Graduate School of Medical Sciences, Japan

Abstract CV

[PL02] Plenary Session 2 September 11 (Thu), 13:00-14:20		Room A
Chair(s)	Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)

13:00-13:40

New Concepts and Future Perspectives of CD7 CAR T-cell Therapy for Hematologic Malignancy

Peihua Lu

Lu Daopei Hospital, China

Abstract CV
13:40-14:20

Post-Transplantation Cyclophosphamide: From Revolution to Evolution in Allogeneic HSCT

Leo Luznik

Baylor College of Medicine, USA

CV

[JS01] Joint Symposium 1 (ASTCT-KSBMT): Real-world Experiences in Optimization of Conditioning Regimen and GVHD Prophylaxis September 11 (Thu), 14:30-16:00		Room A
Chair(s)	Ho Joon Im (University of Ulsan College of Medicine, Korea) Ryotaro Nakamura (City of Hope National Medical Center, USA)

14:30-15:00

Conditioning Intensity and the Role of TBI: Disease Control vs. GVHD Risk

Ryotaro Nakamura

City of Hope National Medical Center, USA

Abstract CV
15:00-15:30

Optimization of Donor and GVHD Prophylaxis with New Agents in the PTCY Era

Stefan O. Ciurea

University of California, Irvine, USA

Abstract CV
15:30-16:00

Evolution and Optimization of Conditioning Regimens in Acute Leukemia: A Korean Perspective

Jae-Ho Yoon

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[SS01] Scientific Session 1: Innovative Cell & Gene Therapy September 11 (Thu), 14:30-16:00		Room B
Chair(s)	Deok Hwan Yang (Chonnam National University Medical School, Korea) Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)

14:30-15:00

In vivo CAR-T Cell Generation

Byoung Ryu

Legend Biotech, USA

Abstract CV
15:00-15:30

Cancer Immunotherapy by γδ T Cells

Lawrence S. Lamb, Jr.

IN8Bio, Inc., USA

Abstract CV
15:30-16:00

Enhancing anti-CD19 CAR-T/-NK Therapies by Mitigating Trogocytosis and Promoting Serial Killing

Duck Cho

Sungkyunkwan University School of Medicine, Korea

Abstract CV

[SS02] Scientific Session 2: Considerations for Optimal Allogeneic HSCT: Donor Age and Reducing Risk of Graft Failure September 11 (Thu), 14:30-16:00		Room C
Chair(s)	Joon Seong Park (Ajou University School of Medicine, Korea) Young Rok Do (Keimyung University School of Medicine, Korea)

14:30-15:00

HSCT Guidelines for Aplastic Anemia: Optimizing Strategies in the Era of Novel Agents

Austin Kulasekararaj

King's College Hospital NHS Foundation Trust, UK

Abstract CV
15:00-15:30

Treatment of Patients with Donor-Specific Anti-HLA Antibodies

Piyanuch Kongtim

University of California, Irvine, USA

Abstract CV
15:30-16:00

The Effect of Donor Age on HSCT Outcomes

Ji Eun Jang

Yonsei University College of Medicine, Korea

Abstract CV

[ES01] Education Session 1: Advances in Transplantation Practice September 11 (Thu), 14:30-16:00		Room D
Chair(s)	Hyeon-Seok Eom (National Cancer Center, Korea) Seongsoo Jang (University of Ulsan College of Medicine, Korea)

14:30-15:00

MRD Monitoring after HSCT

Saeam Shin

Yonsei University College of Medicine, Korea

Abstract CV
15:00-15:30

Optimizing Peripheral Blood Stem Cell Mobilization and Collection

Gi June Min

College of Medicine, The Catholic University of Korea, Korea

Abstract CV
15:30-16:00

Epstein-Barr Virus-Associated Lymphoma: Current Understanding and Treatment Strategies

Hee Young Ju

Sungkyunkwan University School of Medicine, Korea

Abstract CV

[JS02] Joint Symposium 2 (EBMT-KSBMT): The New Era of CAR-T Cell Therapy September 11 (Thu), 16:40-18:20		Room A
Chair(s)	Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Anna Sureda (Catalan Institute of Oncology, Spain)

16:40-17:05

CAR-T Cell Therapy in RR B-ALL

Sebastian Giebel

Maria Sklodowska-Curie National Research Institute of Oncology, Poland

Abstract CV
17:05-17:30

CAR-T Cell Therapy in B-Cell Lymphoma

Gloria Iacoboni

Vall d’Hebron University Hospital, Spain

Abstract CV
17:30-17:55

Current Status of CAR-T and Experiences in Korea

Sang Eun Yoon

Sungkyunkwan University School of Medicine, Korea

Abstract CV
17:55-18:20

Allogeneic HSCT after CAR-T Cell Therapy

Jae Wook Lee

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[SS03] Scientific Session 3: Advancing Hematology through AI and Big Data: From Research to Clinical Application September 11 (Thu), 16:40-18:10		Room B
Chair(s)	Chul Won Choi (Korea University College of Medicine, Korea) Jin Seok Kim (Yonsei University College of Medicine, Korea)

16:40-17:10

Transforming Hematopathology: AI-Driven Insights into Myeloproliferative Neoplasm

Daniel Royston

University of Oxford, UK

Abstract CV
17:10-17:40

Artificial Intelligence in Hematology and Oncology

Jan-Niklas Eckardt

University Hospital Dresden, Germany

Abstract CV
17:40-18:10

Application of Large Language Models in Hematology Research and Scientific Writing

Sang-Hyun Hwang

University of Ulsan College of Medicine, Korea

Abstract CV

[SS04] Scientific Session 4: Understanding and Targeting Clonal Hematopoiesis September 11 (Thu), 16:40-18:10		Room C
Chair(s)	Sung-Soo Yoon (Seoul National University College of Medicine, Korea) Myung Geun Shin (Chonnam National University Medical School, Korea)

16:40-17:10

Therapeutic Targeting of Clonal Hematopoiesis

Steven Chan

University of Toronto, Canada

Abstract CV
17:10-17:40

Understanding and Targeting Poor-Prognostic Leukemia through Physiologically Relevant Animal Models and Integrative Functional Screens

Daichi Inoue

The University of Osaka, Japan

Abstract CV
17:40-18:10

Clonal Hematopoiesis in Human Disease: From Non-Malignant Disease to Malignancy

Youngil Koh

Seoul National University College of Medicine, Korea

Abstract CV

[SA01] Satellite Symposium 1 (Korea Otsuka Pharmaceutical) September 12 (Fri), 08:30-09:00		Room C
Chair(s)	Seok Lee (Ewha Womans University College of Medicine, Korea)

08:30-09:00

Ponatinib and Chemotherapy for Adult Patients with Newly Diagnosed Ph+ ALL Based on the PhALLCON Trial

Gong Benfa

Chinese Academy of Medical Sciences, China

Abstract CV

[SA02] Satellite Symposium 2 (BMS Korea) September 12 (Fri), 08:30-09:00		Room D
Chair(s)	Kyoo-Hyung Lee (Ewha Womans University College of Medicine, Korea)

08:30-09:00

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Andre Schuh

University Health Network, Canada

Abstract CV

[OP05] Oral Presentation 5
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Ho Sup Lee (Kosin University College of Medicine, Korea) Yoon Seok Choi (Korea University College of Medicine, Korea)
Speaker(s)	09:00-09:10	Nespecabtagene Autoleucel (AT101) Demonstrates High Efficacy in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Interim Results of a Phase 2 Study Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
	09:10-09:20	Real-World Clinical Outcomes of Tisagenlecleucel in Relapsed or Refractory DLBCL: A Single-Center Retrospective Study Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
	09:20-09:30	Real-World Outcomes of Tisagenlecleucel versus Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Large B-cell Lymphomas Tong-Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	High-Risk Extranodal NK/T-Cell Lymphoma Patients Could Benefit More from Allogeneic Hematopoietic Stem Cell Transplantation as Consolidation: A Real-World Multicenter Analysis in China Yi Xia (Peking University People's Hospital, China)
	09:40-09:50	Outcomes of Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Analysis from the Taiwan Blood and Marrow Transplantation Registry Po-Tsen Liu (College of Medicine, National Cheng Kung University, Taiwan)
	09:50-10:00	Frequency, Characteristics, Management, and Outcomes of Posttransplant Lymphoproliferative Disorders after Allogeneic HSCT in Children, 15 Years Experience: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group Fatih Erbey (Koc University School of Medicine, Türkiye)

[OP06] Oral Presentation 6
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Min Kyoung Kim (Yeungnam University College of Medicine, Korea) Seong Hyun Jeong (Ajou University School of Medicine, Korea)
Speaker(s)	09:00-09:10	Impact of Donor Age on Survival Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome Dong Hyun Kim (Seoul National University College of Medicine, Korea)
	09:10-09:20	Long-Term Outcomes and Prognostic Factors Following Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndrome: A Nationwide Population-Based Study in Korea Eun Sang Yi (Korea University College of Medicine, Korea)
	09:20-09:30	Impact of Letermovir Prophylaxis on the Pattern of CMV Events and Its Association with Relapse in Allogenic HSCT Recipients for Myelodysplastic Syndromes Sin Young Park (Seoul National University Hospital, Korea)
	09:30-09:40	Impact of Pre-Transplant Cytoreductive Therapy on Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes with Excess of Blasts: A Retrospective Analysis Yu-eun Lee (University of Ulsan College of Medicine, Korea)
	09:40-09:50	Incidence and Risk Factors for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis Yu-Qian Sun (Peking University People's Hospital, China)
	09:50-10:00	Association between Splenomegaly and Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis Patients So Yeon Park (College of Medicine, The Catholic University of Korea, Korea)

[OP07] Oral Presentation 7
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Ho-Young Yhim (Jeonbuk National University Medical School, Korea)
Speaker(s)	09:00-09:10	The Efficacy of Combination Treatment with All-Trans Retinoic Acid, Bortezomib, and Natural Killer cells on CD44-Overexpressing Myeloma Van-Tan Nguyen (Chonnam National University Medical School, Korea)
	09:10-09:20	Preclinical Study of IL-15 Armored Chimeric Antigen Receptor - Natural Killer Cells for Multiple Myeloma Ga-Young Song (Chonnam National University Medical School, Korea)
	09:20-09:30	Automated, Computational Interpretation of Multiparametric Flow Cytometry Based-Minimal Residual Disease for Multiple Myeloma (CAREMM-2401 Study) Ka Young Kim (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	Cost-Effectiveness of Expanding Autologous Stem Cell Transplantation Eligibility to Patients Aged 65 to 70 Years with Multiple Myeloma: A Nationwide Cohort Study in Korea Suein Choi (College of Medicine, The Catholic University of Korea, Korea)
	09:40-09:50	Retrospective Analysis of Medical Costs and Length of Initial Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation Ayako Takarada (University of Tsukuba, Japan)
	09:50-10:00	Improving Pre-Admission Readiness for HSCT Patients: Outcomes of a Structured Nursing-Led Quality Improvement Program Pei-Yu Lo (Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan)

[OP08] Oral Presentation 8
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Eun Sun Yoo (Ewha Womans University College of Medicine, Korea) Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
Speaker(s)	09:00-09:10	Impact of Oral and Gut Microbiome Dysbiosis on Treatment Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Suejung Jo (College of Medicine, The Catholic University of Korea, Korea)
	09:10-09:20	Hematopoietic Stem Cell Transplantation for Congenital Dyserythropoietic Anemia Jeong A Park (Inha University College of Medicine, Korea)
	09:20-09:30	Quadruple Immunotherapy for Paediatric Patients with Relapsed or Refractory Neuroblastoma Pamela Lee (The University of Hong Kong, China)
	09:30-09:40	Busulfan–Melphalan versus Carboplatin–Etoposide–Melphalan as High-Dose Chemotherapy for High-Risk Neuroblastoma in Taiwan: A Single-Center Retrospective Study Chiao-Yu Cheng (National Taiwan University Children's Hospital, Taiwan)
	09:40-09:50	Outcomes of Salvage Treatment Including High-dose Chemotherapy and Autologous Stem Cell Transplantation of Recurrent Central Nervous System Germ Cell Tumors Suhyun Yoon (University of Ulsan College of Medicine, Korea)
	09:50-10:00	Treatment Outcomes of Medulloblastoma: Efficacy of Reduced-Dose Radiotherapy, Intrathecal Methotrexate, and Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation Hee Won Cho (Sungkyunkwan University School of Medicine, Korea)

[JS03] Joint Symposium 3 (East Asia Collaborative Session): Stem Cell Transplantation in Diffuse Large B-cell Lymphoma in the Era of Immunotherapy September 12 (Fri), 10:10-11:50		Room A
Chair(s)	Je-Jung Lee (Chonnam National University Medical School, Korea) Chi-Cheng Li (Hualien Tzu Chi Hospital, Taiwan)

10:10-10:35

Optimizing Autologous Stem Cell Transplantation in the Age of CAR T-cell Therapy: Still a Standard?

Jieun Uhm

Hanyang University College of Medicine, Korea

Abstract CV
10:35-11:00

Treatment Options after CAR T-cell Failure in Diffuse Large B-cell Lymphoma

Shinichi Makita

National Cancer Center Hospital, Japan

Abstract CV
11:00-11:25

Clinical Practice and System Innovation of CAR T-Cell Therapy

Aibin Liang

Tongji Hospital Affiliated to Tongji University, China

Abstract CV
11:25-11:50

Immune Reconstitution after CAR T-cell Therapy vs. Stem Cell Transplantation: Mechanistic Insights and Clinical Implications

Tai-Chung Huang

National Taiwan University Hospital, Taiwan

Abstract CV

[SS05] Scientific Session 5 (KAICET-Cell Therapy Committee Joint Session): Next-Generation Immune Cell Therapies: From Design to Clinical Application September 12 (Fri), 10:10-11:40		Room B
Chair(s)	Kyung-Mi Lee (Korea University College of Medicine, Korea) Hyoung Jin Kang (Seoul National University College of Medicine, Korea)

10:10-10:40

Enhancing CAR-T Cell Function through Membrane-Anchored Cytokines

Hyung Cheol Kim

Curocell Inc., Korea

Abstract CV
10:40-11:10

The Mechanism of Immune Synapse Formation and Its Application to Synapse-Fortified CAR T Cells

Eun Young Choi

Seoul National University College of Medicine, Korea

Abstract CV
11:10-11:40

From Bench to Bedside: The Promise of Engineered NK Cell Therapy

Katy Rezvani

The University of Texas MD Anderson Cancer Center, USA

Abstract CV

[SS06] Scientific Session 6: GVHD Update: Evolving Paradigms in Diagnosis and Therapy September 12 (Fri), 10:10-11:40		Room C
Chair(s)	Hyeoung-Joon Kim (Chonnam National University Medical School, Korea) Hoon Kook (Chonnam National University Medical School, Korea)

10:10-10:40

Clinical Approach of GvHD Bronchiolitis Obliterans Syndrome - Early Detection, Diagnosis, Treatment

Guang-Shing Cheng

Fred Hutchinson Cancer Center, USA

Abstract CV
10:40-11:10

Novel Therapeutic Options in Chronic GVHD

Corey Cutler

Dana-Farber Cancer Institute, USA

Abstract CV
11:10-11:40

FDA-approved Therapies for Chronic GVHD

Robert Zeiser

University Medical Center Freiburg, Germany

Abstract CV

[ES02] Education Session 2: Smart Research Practices: From Data Analysis to Writing September 12 (Fri), 10:10-11:40		Room D
Chair(s)	Hawk Kim (Ewha Womans University College of Medicine, Korea) Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)

10:10-10:40

Medical Research and Scientific Writing Using AI

Yohan Koo

CHA University, Korea

Abstract CV
10:40-11:10

Scientific Writing in BMT and Cellular Therapy Research

Mohamad Mohty

Saint-Antoine Hospital, France

Abstract CV
11:10-11:40

HSCT Research Using Easy R (EZR) Focusing on Survival Analysis

Yoshinobu Kanda

Jichi Medical University, Japan

Abstract CV

[LS05] Luncheon Symposium 5 (Novartis Korea) September 12 (Fri), 12:00-12:40		Room A
Chair(s)	Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

12:00-12:40

Optimizing Fabhalta Therapy: Strategies and Best Practices in PNH Patients

Austin Kulasekararaj

King's College Hospital NHS Foundation Trust, UK

CV

[LS06] Luncheon Symposium 6 (Handok Inc.) September 12 (Fri), 12:00-12:40		Room B
Chair(s)	Je-Hwan Lee (University of Ulsan College of Medicine, Korea)

12:00-12:40

Optimising Transplant Potential in older AML Patients: Insights from Real-World Data

Thomas Schroeder

University Hospital Essen, Germany

Abstract CV

[LS07] Luncheon Symposium 7 (DKSH Korea) September 12 (Fri), 12:00-12:40		Room C
Chair(s)	Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

12:00-12:40

Optimizing Neutropenia Management in Lymphoma Patients: Clinical Insights and Future Directions of G-CSF Therapy

Young Woo Jeon

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[LS08] Luncheon Symposium 8 (MSD Korea) September 12 (Fri), 12:00-12:40		Room D
Chair(s)	Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)

12:00-12:40

An Update on the Efficacy and Safety Profile of 200-day Prevymis Therapy and Q&A

Michelle Yong

Peter MacCallum Cancer Centre, Australia

Abstract CV

[SS07] Scientific Session 7: Transplantation and Relapse: Evidence and Practice Updates September 12 (Fri), 13:00-14:30		Room A
Chair(s)	Ho-Jin Shin (Pusan National University School of Medicine, Korea) Sung-Yong Kim (Konkuk University School of Medicine, Korea)

13:00-13:30

Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia

Partow Kebriaei

The University of Texas MD Anderson Cancer Center, USA

Abstract CV
13:30-14:00

Role of MRD Monitoring and Maintenance Therapy after HSCT in TP53 altered AML or MDS

David Sallman

H. Lee Moffitt Cancer Center & Research Institute, USA

Abstract CV
14:00-14:30

Donor Lymphocyte Infusion Strategy: Korean Institutional Perspective

Silvia Park

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[SS08] Scientific Session 8: Advances in Pediatric Transplantation and Cellular Therapy September 12 (Fri), 13:00-14:30		Room B
Chair(s)	Hyeon Jin Park (National Cancer Center, Korea) Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)

13:00-13:30

CAR T Cell Therapies for Pediatric Solid Tumors

Francesca Del Bufalo

IRCCS Bambino Gesù Children's Hospital, Italy

Abstract CV
13:30-14:00

The Optimal Conditioning for Allo-HSCT in Children with ALL (FORUM Trial)

Krzysztof Kalwak

Wroclaw Medical University, Poland

Abstract CV
14:00-14:30

Management of Post-HSCT Relapse in Pediatric Leukemia

Jae Won Yoo

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[NS01] Nursing Session 1: Multidisciplinary Approach to Treatment after Hematopoietic Stem Cell Transplantation l (KOR.) September 12 (Fri), 13:00-14:30		Room C
Chair(s)	EunJung Joo (National Cancer Center, Korea)

13:00-13:30

Optimizing Endocrine Outcomes after Hematopoietic Stem Cell Transplantation

Daham Kim

Yonsei University College of Medicine, Korea

Abstract CV
13:30-14:00

Acute Kidney Injury after Hematopoietic Stem Cell Transplantation

Junseok Jeon

Sungkyunkwan University School of Medicine, Korea

Abstract CV
14:00-14:30

Psychosocial Distress in Hematopoietic Stem Cell Transplantation

Eun-Seung Yu

The Cyber University of Korea, Korea

Abstract CV

[ES03] Education Session 3: Optimizing Outcomes in HSCT September 12 (Fri), 13:00-14:30		Room D
Chair(s)	Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea)

13:00-13:30

Intensity of Conditioning Regimen (Evolution of Conditioning Regimen)

Yong Park

Korea University College of Medicine, Korea

Abstract CV
13:30-14:00

Advances in GVHD Prophylaxis: From ATG to Post-Transplant Cyclophosphamide (PTCy)

Joon Ho Moon

Kyungpook National University School of Medicine, Korea

CV
14:00-14:30

Second Malignancy after HSCT

Daehun Kwag

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[PS01] Presidential Symposium September 12 (Fri), 14:40-15:20		Room A
Chair(s)	Ho Joon Im (University of Ulsan College of Medicine, Korea)

14:40-15:20

AML-Specific Therapeutics: Integrating Risk-Stratified Transplantation and Immunotherapeutic Targeting

Soheil Meshinchi

Fred Hutchinson Cancer Center, USA

Abstract CV

[PL03] Plenary Session 3 September 12 (Fri), 15:20-16:00		Room A
Chair(s)	Seong Kyu Park (Soonchunhyang University College of Medicine, Korea)

15:20-16:00

Personalized Conditioning Strategies in Allogeneic HSCT: Balancing Disease Control and Toxicity Across Age Groups

Mohamad Mohty

Saint-Antoine Hospital, France

Abstract CV

[DS01] Debate Session 1: Splenectomy Prior to HSCT in Myelofibrosis: Necessity or Risk? September 12 (Fri), 16:40-18:20		Room A
Chair(s)	Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)

16:40-16:55

Necessity

Ik-Chan Song

Chungnam National University College of Medicine, Korea

Abstract CV
16:55-17:10

Risk

Yunsuk Choi

University of Ulsan College of Medicine, Korea

Abstract CV

[DS02] Debate Session 2: Donor Selection for HSCT in Pediatric Leukemia: Haploidentical versus Other Alternative Donor September 12 (Fri), 16:40-18:20		Room A
Chair(s)	Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)

17:30-17:45

Haploidentical

Sung Han Kang

University of Ulsan College of Medicine, Korea

CV
17:45-18:00

Alternative Unrelated Donors (including Cord Blood)

Kyung Taek Hong

Seoul National University College of Medicine, Korea

Abstract CV

[JS04] Joint Symposium 4 (JSTCT-KSBMT): Transplant Strategies to Overcome MRD Positive Hematologic Malignancies September 12 (Fri), 16:40-18:20		Room C
Chair(s)	Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Takanori Teshima (Hokkaido University, Japan)

16:40-17:05

Defining MRD Response Through LSC Detection: A TIM-3–Based Flow Cytometric Perspective

Teppei Sakoda

Kyushu University Hospital, Japan

Abstract CV
17:05-17:30

Transplantation & Management of High-risk ALL with Poor MRD Response

Yu Akahoshi

National Cancer Center Hospital, Japan

Abstract CV
17:30-17:55

Integrating Flow Cytometry-Based MRD into Transplant and Maintenance Strategies in MM

Ari Ahn

College of Medicine, The Catholic University of Korea, Korea

Abstract CV
17:55-18:20

Transplantation & Management of High-risk MM with Poor MRD Response

Hyunsoo Cho

Seoul National University Hospital, Korea

CV

[ES04] Education Session 4: Infectious Complication September 12 (Fri), 16:40-18:10		Room D
Chair(s)	Jun Eun Park (Korea University College of Medicine, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea)

16:40-17:10

Infection Prophylaxis in CAR T-Cell Therapy

Ji Hyun Lee

Dong-A University College of Medicine, Korea

Abstract CV
17:10-17:40

Should a Well-Cooked Diet Be Recommended for Transplant Patients?

Annalisa Paviglianiti

Hospital de la Santa Creu i Sant Pau, Spain

Abstract CV
17:40-18:10

Viral Infection after HSCT

Seung-Ji Kang

Chonnam National University Medical School, Korea

Abstract CV

[SA03] Satellite Symposium 3 (GC Biopharma) September 13 (Sat), 08:30-09:00		Room C
Chair(s)	Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)

08:30-09:00

Role of IVIG in Stem Cell Transplantation and Immunotherapy in Hematologic Disease

Dae-Ho Choi

Sungkyunkwan University School of Medicine, Korea

Abstract CV

[SA04] Satellite Symposium 4 (GlaxoSmithKline) September 13 (Sat), 08:30-09:00		Room D
Chair(s)	Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)

08:30-09:00

Role of Momelotinib in the Treatment of Myelofibrosis with Anemia

Seo-Yeon Ahn

Chonnam National University Medical School, Korea

Abstract CV

[JS05] Joint Symposium 5 (ISCT-KSBMT): Bridging Cell Therapy and Hematopoietic Stem Cell Transplantation September 13 (Sat), 09:00-10:30		Room A
Chair(s)	Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea) William Hwang (National Cancer Centre Singapore and Singapore General Hospital, Singapore)

09:00-09:30

Going Beyond Conventional CAR T Cell Therapies for Treatment of Blood Cancer and Other Diseases

William Hwang

National Cancer Centre Singapore and Singapore General Hospital, Singapore

Abstract CV
09:30-10:00

Virus-Specific T-Cell Therapy: The Ultimate Weapon in the Endless Battle Against Post-Transplant Viral Infections

Seok-Goo Cho

College of Medicine, The Catholic University of Korea, Korea

Abstract CV
10:00-10:30

Mesenchymal Stroma Cells (MSC) in Autoimmune Diseases: Clinical Application in Systemic Sclerosis and in Systemic Lupus Erythematosus

Dominique Farge

AP-HP, Saint-Louis Hospital, France

Abstract CV

[SS09] Scientific Session 9: Navigating Critical HSCT Complications September 13 (Sat), 09:00-10:30		Room C
Chair(s)	June-Won Cheong (Yonsei University College of Medicine, Korea) Hyo Jung Kim (Hallym University College of Medicine, Korea)

09:00-09:30

HokUS Scoring System for Predicting the Onset and Outcome of SOS

Souichi Shiratori

Hokkaido University Faculty of Medicine, Japan

Abstract CV
09:30-10:00

Diagnosis and Management of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Sonata Jodele

Cincinnati Children’s Hospital Medical Center, USA

Abstract CV
10:00-10:30

Post-HSCT Viral Management: Strategies Beyond the Guidelines

Raeseok Lee

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[SS10] Scientific Session 10: Immunotherapy and Transplantation in Myeloid Malignancies: Evolving Strategies and Clinical Advances September 13 (Sat), 09:00-10:30		Room D
Chair(s)	Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea)

09:00-09:30

Evolving Paradigms in AML: How Transplantation Fits in the Modern Therapeutic Landscape

Musa Yilmaz

The University of Texas MD Anderson Cancer Center, USA

Abstract CV
09:30-10:00

Immune Checkpoint Modulation in Myeloid Malignancies: Will We Find Success Soon?

Amer M. Zeidan

Yale Cancer Center, USA

Abstract CV
10:00-10:30

Augmenting NK-cell Immunity for the Treatment of Myeloid Malignancies using Hypomethylating Agents

Junshik Hong

Seoul National University College of Medicine, Korea

Abstract CV

[JS06] Joint Symposium 6 (TSBMT-KSBMT): Chronic GVHD or Rare Transplantation Related Complications September 13 (Sat), 10:40-11:40		Room A
Chair(s)	Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) Hakan Goker (Hacettepe University Medical School, Türkiye)

10:40-11:10

Pathophysiology and Management of Chronic GVHD

Hakan Goker

Hacettepe University Medical School, Türkiye

Abstract CV
11:10-11:40

Neurologic Complications Following Hematopoietic Stem Cell Transplantation: Focus on Central Nervous System Graft-versus-Host Disease

Jin Kyung Suh

University of Ulsan College of Medicine, Korea

Abstract CV

[SS11] Scientific Session 11: Maximizing MM Treatment: Integrating Transplantation, Maintenance, and Novel Immunotherapies September 13 (Sat), 10:40-12:10		Room C
Chair(s)	Soo-Mee Bang (Seoul National University College of Medicine, Korea) Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)

10:40-11:10

Do We Need ASCT for MM Patients in the New Agent Era?

Thierry Facon

Lille University Hospital, France

CV
11:10-11:40

Autologous NK Cell Therapy as a Consolidative Strategy after Auto-SCT

Evren Alici

Karolinska Institutet, Sweden

Abstract CV
11:40-12:10

The Role of Salvage Auto-HSCT in RRMM Patients

Jongheon Jung

National Cancer Center, Korea

Abstract CV

[NS02] Nursing Session 2: Multidisciplinary Approach to Treatment after Hematopoietic Stem Cell Transplantation ll (KOR.) September 13 (Sat), 10:40-11:40		Room D
Chair(s)	Heejun Kim (Samsung Medical Center, Korea)

10:40-11:10

How Can We Reduce Liver-Related Morbidity and Mortality in Patients after HSCT?

Pil Soo Sung

College of Medicine, The Catholic University of Korea, Korea

Abstract CV
11:10-11:40

Practical Oral Care for HSCT

Jusik Kim

Seoul National University College of Medicine, Korea

Abstract CV

Scientific Program